CA057-003

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

Trial status

Accepting patients

Phase
Phase 1/2
Enrollment
220
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There are 5 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • BMS-986158 is a kind of drug called a Bromodomain and Extraterminal (BET) inhibitor. Researchers think BMS-986158 may work by blocking cancer cells from turning on proteins that help them to grow.
  • Dexamethasone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
  • Mezigdomide is a Cereblon (CRBN) binding compound currently under clinical investigation for multiple myeloma.
  • Tazemetostat is an EZH2 inhibitor that helps stop the spread of cancer cells.
  • Trametinib is a cancer medication that interferes with the growth and spread of cancer cells in the body.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.